uBreakiFix Tech Repair Franchise Grows O'ahu Footprint, Opens in Aiea
OAHU, Hawaii, May 1, 2025 /PRNewswire/ — Leading tech repair provider uBreakiFix® by Asurion has opened its newest franchise location in Aiea at 98-127 Kaonohi Street in Pearlridge Center, right next to Anna Miller's and Tamuras. The store offers professional fixes for most consumer electronics, from smartphones, tablets, and computers to game consoles, smart speakers, drones, and more.
While common repairs include cracked screens, battery issues, and liquid damage, uBreakiFix repair experts have fixed millions of devices and can help with nearly any tech mishap, with most repairs completed the same day. The store also offers tech support services like virus removal, data backup and transfer, and tune-ups for devices that have become sluggish over time, as well as preventative care services like device cleanings.
'We are excited to serve more people in O'ahu with fast and affordable tech repair,' said uBreakiFix CEO Dave Barbuto. 'We all rely on our phones and laptops more than ever before, and at uBreakiFix our mission is bigger than repairing shattered screens and broken charge ports. We fix tech because people rely on tech to stay connected to things that are important to them. We look forward to serving this community through our new location.'
uBreakiFix stores fix all types of electronics, regardless of make or model. The stores are authorized service providers for Samsung Galaxy® smartphones, Google Pixel™ smartphones, Xbox® game consoles, Microsoft Surface® devices, and more. uBreakiFix stores also have access to Apple® genuine parts, tools and manuals as part of Apple's Independent Repair Provider network.
uBreakiFix offers free, no-obligation diagnostics on all gadgets, as well as a low-price guarantee and 1-year warranty on all repairs. The new store brings the company's retail footprint to nearly 700 locations across the U.S. For more information, to view a service menu, or to book a repair appointment, visit ubreakifix.com/locations/aiea. Walk-in service is also available at the Aiea location.
uBreakiFix Aiea is located at:uBreakiFix by Asurion98-127 Kaonohi St, Aiea, HI 96701 (808) 762-4349 (IFIX)
About uBreakiFix by Asurion
uBreakiFix by Asurion stores specialize in the repair of consumer technology, including smartphones, game consoles, tablets, computers and nearly everything in between. Cracked screens, software issues, camera issues and most other problems can be repaired by visiting uBreakiFix stores across the U.S. Since 2016, uBreakiFix has served as a walk-in repair partner for Google Pixel customers. In 2018, uBreakiFix became a Samsung Care authorized service provider offering same-day, in-person support for Samsung Galaxy customers across the U.S. In 2019, uBreakiFix joined the Asurion family and now operates as a subsidiary of the tech care company while still maintaining the franchise model. For more information, visit ubreakifix.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
31 minutes ago
- Malaysian Reserve
NAPA Anesthesia Honored with RPI Best Practice Standards® Award for Excellence in Employee Recognition
SUNRISE, Fla., July 23, 2025 /PRNewswire/ — North American Partners in Anesthesia (NAPA), the nation's largest single-specialty anesthesia services organization, has been awarded a 2025 Best Practice Standards® Award by Recognition Professionals International (RPI). NAPA was honored for NAPApplause, which fosters a culture where employees feel valued for their contributions and connected to NAPA's mission to be the "Destination of Choice for All." NAPA joins American Airlines, Banfield Pet Hospital, General Dynamics Information Technology, and Liberty Mutual Insurance in receiving awards for recognition excellence through programs aligned with RPI's seven Best Practice Standards®. "We believe a comprehensive recognition approach that integrates formal and informal appreciation is essential to our success," said Ian Kearney, Vice President of People & Organization at NAPA. "This includes peer-to-peer feedback, milestone recognition, performance awards, and wellness-based incentives." NAPApplause celebrates the meaningful contributions of NAPA team members, from major milestones to everyday moments that make a difference. "When people feel seen and appreciated, they are more motivated to bring their best every day," said Jill Duca, Senior Manager of Organizational Effectiveness at NAPA. To date, NAPA employees have submitted more than 250 formal award nominations through NAPApplause, and within weeks of launching a new peer feedback feature in 2025, nearly 100 appreciation messages were shared between colleagues. The RPI Best Practice Standards® are based on academic research and real-world implementation across organizations of all sizes. Each standard offers a framework for designing recognition programs that promote employee engagement, enhance culture, and drive business outcomes. About North American Partners in Anesthesia As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. NAPA has grown to become the nation's single-specialty leader in anesthesia. Our nearly 5,000 clinicians serve more than 2 million patients annually at nearly 400 healthcare facilities in 23 states. For more information, please visit About Recognition Professionals International Recognition Professionals International (RPI) is a Strategic Industry Group (SIG) within the Incentive Marketing Association. RPI is the only professional association at the forefront of workforce recognition through its sole focus on recognition innovations and education as a systematic method for improvements in the workplace. RPI members are recognition experts who practice the art of recognition at their companies and recognition solution providers who provide recognition services, tools and platforms to companies as a service (including consultation, program design and technology).
Malaysian Reserve
2 hours ago
- Malaysian Reserve
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement in early intervention for multiple myeloma SAN DIEGO, July 23, 2025 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that Janssen-Cilag International NV, a Johnson & Johnson company, received European Commission (EC) approval of a new indication for DARZALEX Faspro® (daratumumab) co-formulated with ENHANZE®, as monotherapy for the treatment of adult patients with smouldering multiple myeloma (SMM) at high-risk of developing multiple myeloma. 'This approval reinforces DARZALEX Faspro with ENHANZE as a foundational treatment across all stages of multiple myeloma,' said Dr. Helen Torley, President and CEO of Halozyme. 'We are pleased that the new treatment paradigm addresses the critical needs of people living with this complex blood disease.' SMM is an asymptomatic intermediate disease state of multiple myeloma where abnormal cells can be detected in the bone marrow. The current standard of care for SMM, even in high-risk cases, is active monitoring (or 'Watch and Wait') to track for signs of biochemical progression and/or end-organ damage. This means therapeutic intervention is only offered when the disease progresses. The EC approval is supported by data from the Phase 3 AQUILA study (NCT03301220), evaluating the efficacy and safety of fixed-duration monotherapy daratumumab SC compared with active monitoring in those with high-risk SMM. For more information on the study and its findings, please view Johnson & Johnson's press release issued on July 23, 2025. About Halozyme Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in ten commercialized products in at least one major region and across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals. Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with Teva Pharmaceuticals and McDermott Laboratories Limited, an affiliate of Viatris Inc. Halozyme is headquartered in San Diego, CA and has offices in Ewing, NJ and Minnetonka, MN. Minnetonka is also the site of its operations facility. For more information visit and connect with us on LinkedIn and Twitter. Safe Harbor Statement In addition to historical information, the statements set forth above include forward-looking statements including, without limitation, statements concerning the possible activity, benefits and attributes of ENHANZE®, the possible method of action of ENHANZE®, its potential application to aid in the dispersion and absorption of other injected therapeutic drugs, and statements concerning certain other potential benefits of ENHANZE® including facilitating more rapid delivery of injectable medications through subcutaneous delivery and potentially lowering the treatment burden for patients, including a potential reduction in administration time and broadening the treatment options for the indications referred to in this press release. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. The forward-looking statements are typically, but not always, identified through use of the words 'expect,' 'believe,' 'enable,' 'may,' 'will,' 'could,' 'intends,' 'estimate,' 'anticipate,' 'plan,' 'predict,' 'probable,' 'potential,' 'possible,' 'should,' 'continue,' and other words of similar meaning. Actual results could differ materially from the expectations contained in forward-looking statements as a result of several factors, including unexpected results or delays in the launch or commercialization of our partner's product for the indication referred to in this press release, unexpected adverse events or patient experiences or outcomes from being treated with the ENHANZE® co-formulated treatment referred to in this press release, and competitive conditions. These and other factors that may result in differences are discussed in greater detail in Halozyme's most recent Annual and Quarterly Reports filed with the Securities and Exchange Commission. Except as required by law, Halozyme undertakes no duty to update forward-looking statements to reflect events after the date of this release. Contacts: Tram BuiVP, Investor Relations and Corporate Communications609-333-7668tbui@ Sydney
The Star
8 hours ago
- The Star
Apple and Google face more UK antitrust scrutiny over mobile ecosystems
FILE PHOTO: The Google logo is seen outside the company's offices in London, Britain, June 24, 2025. REUTERS/Carlos Jasso/File Photo LONDON (Reuters) -Britain's competition regulator said it plans to designate Apple and Google with so-called strategic market status for their role in mobile ecosystems, as it steps up scrutiny of what it has described as their duopoly. The plans announced on Wednesday follows findings by an inquiry group at Britain's Competition and Markets Authority (CMA) that a number of markets relating to mobile internet browsers were not working well for consumers or businesses. Apple's Safari and Google's Chrome dominate the mobile browser market on iPhones and Android devices, respectively. A strategic market status (SMS) designation allows the CMA to impose interventions on a firm, such as requiring it to adhere to specific behaviour so as not to undermine fair competition. In Apple and Google's cases, they could be forced to offer more features and give users the option actively to choose their preferred mobile browser, if recommendations from the CMA's inquiry group are accepted. Both Apple and Google pushed back against the CMA's proposals, with Google calling the step "disappointing and unwarranted." "It is ... crucial that any new regulation is evidence-based, proportionate and does not become a roadblock to growth in the UK," Google's senior director for competition, Oliver Bethell, said. Apple said separately it was concerned that the new rules being considered would undermine the privacy and security protections expected by its users. (Reporting by Muvija M and Sam Tabahriti; Editing by Sachin Ravikumar)
